NetraMark【AIAI】銘柄情報

NetraMark Holdings Inc (AIAI) 銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

通貨

0.64

( -8.57% )

買値

0.62

売値

0.65

出来高

53,000

0.62 日の範囲 0.69

0.62 52 週間の範囲 1.12

時価総額

59.359M

前日終値

0.70

始値

0.69

時刻

500

0.64

最終取引時間

01:32:19

財務取引量

VWAP

平均取引量 (3 か月)

$ 46,120

発行済株式数

92,748,699

配当利回り

PER

-10.27

1 株当たり利益 (EPS)

-0.07

歳入

175.85k

純利益

-6.4M

NetraMark Holdings Inc. provides AI-powered insights and software solutions to trial sponsors, clinical research organizations, and biotechnology companies worldwide. It operates NetraAI platform, an advanced machine learning system purpose-built for analyzing complex clinical trial data to identify... NetraMark Holdings Inc. provides AI-powered insights and software solutions to trial sponsors, clinical research organizations, and biotechnology companies worldwide. It operates NetraAI platform, an advanced machine learning system purpose-built for analyzing complex clinical trial data to identify meaningful patient subpopulations. The company was formerly known as Nurosene Health Inc. and changed its name to NetraMark Holdings Inc. in February 2023. NetraMark Holdings Inc. was founded in 2016 and is headquartered in Toronto, Canada. 詳細を表示

セクター

Healthcare

業界

Healthcare Providers & Services

ウェブサイト

www.netramark.com

本社

Toronto, Canada

設立

2026

NetraMark Holdings Inc is listed in the Healthcare sector of the トロント証券取引所 with ticker AIAI. The last closing price for NetraMark was $0.70. Over the last year, NetraMark shares have traded in a share price range of $ 0.62 to $ 1.12.

NetraMark currently has 92,748,699 shares in issue. The market capitalisation of NetraMark is $59.36 million. NetraMark has a price to earnings ratio (PE ratio) of -10.27.

NetraMark Announces Presentation at Sidoti Small Cap Conference on June 18, 2026

TORONTO, June 09, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI...

NetraMark to Present at the American Society of Clinical Psychopharmacology Annual Meeting

TORONTO, May 20, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI...

NetraMark Provides Second Quarter Update and Highlights Continued Commercial, Scientific, Regulatory and Capital Markets Momentum

TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI...

NetraMark Announces Change To Board Of Directors

TORONTO, May 07, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI...

NetraMark Appoints Dr. Panteli Theocharous As Fractional Chief Medical Officer, Strengthening Clinical Leadership To Accelerate Global Adoption of NetraAI

TORONTO, May 04, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI...

NetraMark To Open The Market At The Toronto Stock Exchange On May 5, 2026

TORONTO, April 30, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX:...

NetraMark Positioned to Advance Psychedelic Clinical Trials Following U.S. Executive Order, Supported by Peer-Reviewed Research and Active Programs

TORONTO, April 22, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX:...

Netramark Comments on U.S. Executive Order to Accelerate Treatments for Serious Mental Illness and Highlights the Need for Regulatory‑Grade Trial Design in Psychedelic Development

TORONTO, April 20, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX:...

Netramark-Authored, Peer-Reviewed Article Suggests Psychedelics Might Not Only Affect Brain Chemistry, They May Also Involve Quantum-Level Processes Inside the Brain

Publication strengthens NetraMark's case for biomarker-guided enrichment, individualized response modeling, and...

NetraMark Announces Strategic Oncology Research Collaboration with Fondazione per la Medicina Personalizzata to Analyze Landmark ROME Trial Dataset

TORONTO, March 25, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX:...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-0.18	-21.9512195122	0.82	0.82	0.62	34565	0.7458116	CS
4	-0.21	-24.7058823529	0.85	0.9	0.62	66926	0.84863111	CS
12	-0.19	-22.8915662651	0.83	1.09	0.62	48450	0.8931427	CS
26	-0.38	-37.2549019608	1.02	1.12	0.62	41178	0.9118666	CS
52	-0.38	-37.2549019608	1.02	1.12	0.62	41178	0.9118666	CS
156	-0.38	-37.2549019608	1.02	1.12	0.62	41178	0.9118666	CS
260	-0.38	-37.2549019608	1.02	1.12	0.62	41178	0.9118666	CS

AIAI - Frequently Asked Questions (FAQ)

What is the current NetraMark Holdings Inc share price?

The current share price of NetraMark Holdings Inc is $ 0.64

How many NetraMark Holdings Inc shares are in issue?

NetraMark Holdings Inc has 92,748,699 shares in issue

What is the market cap of NetraMark Holdings Inc?

The market capitalisation of NetraMark Holdings Inc is CAD 59.36M

What is the 1 year trading range for NetraMark Holdings Inc share price?

NetraMark Holdings Inc has traded in the range of $ 0.62 to $ 1.12 during the past year

What is the PE ratio of NetraMark Holdings Inc?

The price to earnings ratio of NetraMark Holdings Inc is -10.27

What is the cash to sales ratio of NetraMark Holdings Inc?

The cash to sales ratio of NetraMark Holdings Inc is 400.86

What is the registered address of NetraMark Holdings Inc?

The registered address for NetraMark Holdings Inc is 1655 Dupont Street, Toronto, Ontario, M6P 3T1

What is the NetraMark Holdings Inc website address?

The website address for NetraMark Holdings Inc is www.netramark.com

Which industry sector does NetraMark Holdings Inc operate in?

NetraMark Holdings Inc operates in the Healthcare Providers & Services sector

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

NetraMark Holdings Inc (AIAI)

NetraMark Holdings Inc (AIAI) 銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

主要統計と詳細

NetraMark Holdings Inc について

AIAI 最新ニュース

NetraMark Announces Presentation at Sidoti Small Cap Conference on June 18, 2026

NetraMark to Present at the American Society of Clinical Psychopharmacology Annual Meeting

NetraMark Provides Second Quarter Update and Highlights Continued Commercial, Scientific, Regulatory and Capital Markets Momentum

NetraMark Announces Change To Board Of Directors

NetraMark Appoints Dr. Panteli Theocharous As Fractional Chief Medical Officer, Strengthening Clinical Leadership To Accelerate Global Adoption of NetraAI

NetraMark To Open The Market At The Toronto Stock Exchange On May 5, 2026

NetraMark Positioned to Advance Psychedelic Clinical Trials Following U.S. Executive Order, Supported by Peer-Reviewed Research and Active Programs

Netramark Comments on U.S. Executive Order to Accelerate Treatments for Serious Mental Illness and Highlights the Need for Regulatory‑Grade Trial Design in Psychedelic Development

Netramark-Authored, Peer-Reviewed Article Suggests Psychedelics Might Not Only Affect Brain Chemistry, They May Also Involve Quantum-Level Processes Inside the Brain

NetraMark Announces Strategic Oncology Research Collaboration with Fondazione per la Medicina Personalizzata to Analyze Landmark ROME Trial Dataset

NetraMark Announces Presentation at Sidoti Small Cap Conference on June 18, 2026

NetraMark to Present at the American Society of Clinical Psychopharmacology Annual Meeting

NetraMark Provides Second Quarter Update and Highlights Continued Commercial, Scientific, Regulatory and Capital Markets Momentum

NetraMark Announces Change To Board Of Directors

NetraMark Appoints Dr. Panteli Theocharous As Fractional Chief Medical Officer, Strengthening Clinical Leadership To Accelerate Global Adoption of NetraAI

NetraMark To Open The Market At The Toronto Stock Exchange On May 5, 2026

NetraMark Positioned to Advance Psychedelic Clinical Trials Following U.S. Executive Order, Supported by Peer-Reviewed Research and Active Programs

Netramark Comments on U.S. Executive Order to Accelerate Treatments for Serious Mental Illness and Highlights the Need for Regulatory‑Grade Trial Design in Psychedelic Development

AIAI - Frequently Asked Questions (FAQ)

AIAI 取引

議論

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

ADVFNに参加する理由

プロトレーダー向けの高機能ツール

広告を削除する